Mentice AB (publ) provides endovascular simulation solutions to teaching entities, healthcare systems, and medical device manufacturers. The company operates through Medical Device Industry, Healthcare Systems, and Strategic Alliances segments. It provides software modules in the areas of acute ischemic stroke intervention, atrial septal defect and patent foramen ovale occlusion, aortic valve implantation, endovascular aortic repair, below-the-knee intervention, carotid intervention, patient-specific simulation, coronary advanced and essentials, coronary intermediate, left atrial appendage occlusion, neurovascular coiling and thrombectomy, peripheral angiography, prostatic artery embolization, radiation safety, renal denervation, renal intervention, thoracic endovascular aortic repair, transarterial chemoembolization, transseptal puncture, uterine artery embolization, peripheral angiography, and vascular trauma and cardiac rhythm management, as well as supports interventionalists to transition from transfemoral to transradial access. The company also offers medical simulators for endovascular therapies, and simulator accessories and extensions for endovascular therapies; silicone vasculature for endovascular simulation; cardiac and vascular flow systems; neurovascular flow systems; mentice right heart cath app, a mobile solution for an interactive real-time exploration into the right heart catheterization procedure; mentice live learning center, a remote learning with its VIST G endovascular simulation platform. Its products are used to educate, train, and enhance the practitioners in skills. The company operates in Europe, the Middle East, and Africa; Asia Pacific region; and the Americas. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.